AGP Executive Report
Last update: 28 minutes agoALS Research: Shanghai’s Zhimeng Biopharma completed enrollment of 255 patients in a pivotal Phase 2/3 trial of its ALS drug, setting up the next stage of testing. Brain Injury: A preliminary Chinese study found improved conscious behaviour in 13 of 24 patients after focused ultrasound; one man regained speech and mobility, but rehabilitation may also have contributed, and the report did not establish whether there was a control group. Patient Safety: Parents in northeast China are seeking answers after one needle was reportedly used on 78 pupils during tuberculosis screening. Healthcare Reach: A Chinese hospital ship treated 5,909 people during a seven-day mission in Ghana. Public Health: Reports highlight the serious risks linked to betel nut use in China, while the country’s population of people aged 65 and older has surpassed the number of children under 15.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
